STERIS Expects FY25 As Reported Revenue From Continuing Operations To Increase 6.5%-7.5%; Adjusted EPS From Continuing Operations Of $9.05 - $9.25 (Est $9.33)
Capital expenditures are anticipated to be approximately $360 million and free cash flow is expected to be approximately $700 million.